CA2839261A1 - Mitigation of cutaneous injury with il-12 - Google Patents

Mitigation of cutaneous injury with il-12 Download PDF

Info

Publication number
CA2839261A1
CA2839261A1 CA2839261A CA2839261A CA2839261A1 CA 2839261 A1 CA2839261 A1 CA 2839261A1 CA 2839261 A CA2839261 A CA 2839261A CA 2839261 A CA2839261 A CA 2839261A CA 2839261 A1 CA2839261 A1 CA 2839261A1
Authority
CA
Canada
Prior art keywords
wound
administration
cutaneous
rmuil
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2839261A
Other languages
English (en)
French (fr)
Inventor
Lena A. Basile
Dolph ELLEFSON
Timothy K. GALLAHER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neumedicines Inc
Original Assignee
Neumedicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neumedicines Inc filed Critical Neumedicines Inc
Publication of CA2839261A1 publication Critical patent/CA2839261A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2839261A 2011-06-13 2012-06-13 Mitigation of cutaneous injury with il-12 Abandoned CA2839261A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161496472P 2011-06-13 2011-06-13
US61/496,472 2011-06-13
US201161528053P 2011-08-26 2011-08-26
US61/528,053 2011-08-26
PCT/US2012/042165 WO2012174056A1 (en) 2011-06-13 2012-06-13 Mitigation of cutaneous injury with il-12

Publications (1)

Publication Number Publication Date
CA2839261A1 true CA2839261A1 (en) 2012-12-20

Family

ID=47357436

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2839261A Abandoned CA2839261A1 (en) 2011-06-13 2012-06-13 Mitigation of cutaneous injury with il-12

Country Status (5)

Country Link
US (1) US9925246B2 (pt-PT)
EP (1) EP2718456B1 (pt-PT)
JP (1) JP6005736B2 (pt-PT)
CA (1) CA2839261A1 (pt-PT)
WO (1) WO2012174056A1 (pt-PT)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3031083A1 (en) * 2016-07-18 2018-01-25 Neumedicines Inc. Uses of il-12 as a replacement immunotherapeutic
JP7045671B2 (ja) * 2018-11-12 2022-04-01 有限会社バイオ研 皮膚塗布用の皮膚創傷治癒促進組成物、その製造方法、及び創傷被覆材
JP7448137B2 (ja) * 2020-03-10 2024-03-12 日本ゼトック株式会社 アクチン重合促進剤

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5457038A (en) 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US5780597A (en) 1989-12-22 1998-07-14 Hoffmann-La Roche Inc. Monoclonal antibodies to cytotoxic lymphocyte maturation factor
US5573764A (en) 1994-01-21 1996-11-12 Genetics Institute, Inc. Use of interleukin-12 to prevent graft versus host disease
WO1996024369A1 (en) 1995-02-06 1996-08-15 Genetics Institute, Inc. Formulations for il-12
US5853714A (en) 1995-03-27 1998-12-29 Genetics Institute, Inc. Method for purification of IL-12
US6423308B1 (en) * 1998-09-15 2002-07-23 Wyeth Treatment of Kaposi's sarcoma with IL-12
US7052685B1 (en) 1998-10-15 2006-05-30 Trustees Of The University Of Pennsylvania Methods for treatment of cutaneous T-cell lymphoma
EP2277910A1 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin fusion proteins
EP1587834B1 (en) 2002-12-23 2011-07-06 Schering Corporation Uses of il-23 mammalian cytokine; related reagents
US7763256B2 (en) * 2002-12-23 2010-07-27 William Marsh Rice University Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
US7939058B2 (en) * 2003-07-03 2011-05-10 University Of Southern California Uses of IL-12 in hematopoiesis
EP1641431B1 (en) * 2003-07-03 2018-01-10 University Of Southern California Uses of il-12 for reducing the toxicity of chemo- and/or radio-therapy
MX2007002134A (es) 2004-08-20 2007-09-14 Smithkline Beecham Corp Metodos para curar heridas administrando interleucina-18 humana.
WO2008067042A2 (en) * 2006-10-10 2008-06-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Modeling wound healing
US20100330046A1 (en) * 2009-05-21 2010-12-30 Stratatech Corporation Human skin substitutes expressing il-12

Also Published As

Publication number Publication date
EP2718456A4 (en) 2014-11-19
WO2012174056A1 (en) 2012-12-20
JP2014517038A (ja) 2014-07-17
JP6005736B2 (ja) 2016-10-12
EP2718456A1 (en) 2014-04-16
US20140205561A1 (en) 2014-07-24
EP2718456B1 (en) 2019-04-24
US9925246B2 (en) 2018-03-27

Similar Documents

Publication Publication Date Title
US7052684B2 (en) Methods of healing wounds and fibrotic disorders using IL-10
CA2081104A1 (en) Use of gm-csf and g-csf to promote accelerated wound healing
EP1899475B1 (en) A composition for wound healing and use thereof
RU2463078C2 (ru) Пластырь, высвобождающий активное соединение
EP3272357A1 (de) Behandlung inflammatorischer krankheiten
US9925246B2 (en) Mitigation of cutaneous injury with IL-12
CA2724308C (en) Method of promoting wound healing
CN107106492B (zh) 用于治疗伤口的组合物
El‐Hakim The effect of fibrin stabilizing factor (F. XIII) on healing of bone defects in normal and uncontrolled diabetic rats
EP2572724A1 (de) Behandlung von Fibrosen und Lebererkrankungen
RU2657806C2 (ru) Способ регионального лечения трофической язвы
US20220347353A1 (en) Methods for treating acute wounds and improving outcomes
US20070053872A1 (en) Treatment of wounds using il-17b
Mateshuk-Vatseba et al. The influence of an opioid on the course of reparative processes
US20240016893A1 (en) Compositions and methods for treating wounds
US20080159979A1 (en) Treatment of wounds using il-17b
CA2669109A1 (en) Il-17b for use in wound healing
Rasheed A Comparative Study on Irrigation Dressing Versus Regular Dressing on Surgically Debrided & Traumatic Wounds
EP0288525A1 (en) Composition for the stimulation of wound healing containing an immunostimulant bacterial exotoxin and use thereof
Shakir et al. Biopatterned Recombinant Human Bone Morphogenetic Protein 2 Does Not Induce Pansynostosis or Growth Restriction in the Immature Craniofacial Skeleton
WO2007018846A2 (en) Use of interferon- tau for reduction of scar tissue formation
Riyaz A Comparative Study of the Efficacy of Topical Hydrogel Dressings and Conventional Dressings in Chronic Wounds
Abid Acceleration of skin wound healing by application of galvanic stimulation in rabbits
Botros et al. Comparative effect of tiaprofenic acid and piroxicam alone and as adjuvants to antibiharzial therapy on pulmonary granuloma in unsensitized mice
Santos et al. Cutaneous leishmaniasis (CL) caused by Leishmania species is a sandfly-transmitted protozoal disease endemic in many trop-ical countries of the Americas, Africa, and Asia. It has been

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170607

FZDE Discontinued

Effective date: 20190904